Edition:
United States

Becton Dickinson and Co (BDX)

BDX on New York Consolidated

207.72USD
18 Oct 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$207.72
Open
--
Day's High
--
Day's Low
--
Volume
25
Avg. Vol
1,171,265
52-wk High
$207.73
52-wk Low
$161.29

Latest Key Developments (Source: Significant Developments)

BD statement on European Commission conditional clearance of Bard acquisition
Wednesday, 18 Oct 2017 10:17am EDT 

Oct 18 (Reuters) - Becton Dickinson and Co :BD statement on European Commission conditional clearance of bard acquisition.Says continue to expect that BD and Bard transaction will close in fourth calendar quarter of 2017​.Says ‍"committed" to divesting certain assets to satisfy conditions requested by European Commission​ for Bard deal.  Full Article

Becton Dickinson and Co announces launch of platform for RNA expression analysis
Tuesday, 12 Sep 2017 07:00am EDT 

Sept 12 (Reuters) - Becton Dickinson and Co ::Becton Dickinson and Co - announces launch of BD rhapsody, a platform for RNA expression analysis.Becton Dickinson and Co - ‍bd rhapsody platform assay offering will be rapidly expanded over next 12 months​.Becton Dickinson and Co - has initiated early access for abseq protein detection on BD rhapsody system, expects commercial availability in H1 2018.Becton Dickinson and Co - ‍ BD rhapsody platform is also being expanded beyond RNA expression to include protein detection​.  Full Article

BD announces extension of exchange offers and consent solicitations for C. R. Bard Inc notes
Tuesday, 29 Aug 2017 06:30am EDT 

Aug 29 (Reuters) - Becton Dickinson And Co :BD announces extension of exchange offers and consent solicitations for C. R. Bard Inc notes.Becton Dickinson And Co - amended exchange offers and consent solicitations to extend expiration date to 12:01 a.m., New York City time, Sept 27, 2017.  Full Article

Retractable Technologies says court dismissed co's case against Becton, Dickinson and Co​
Friday, 18 Aug 2017 03:28pm EDT 

Aug 18 (Reuters) - Retractable Technologies Inc ::On August 17, judge issued court's final judgment regarding RTI's suit against Becton, Dickinson and Co​.Judgment orders that RTI take nothing in its suit against BD and dismisses case​.Considering its options, including motion for new trial or to amend judgment, appeal to fifth circuit court of appeals​.  Full Article

FDA provides update on its investigation into inaccurate results from certain lead tests‍​
Thursday, 17 Aug 2017 06:03pm EDT 

Aug 17 (Reuters) - U.S. Food and Drug Administration-:U.S. FDA provides update on its investigation into inaccurate results from certain lead tests‍​.U.S. FDA - conducted an inspection of Becton Dickinson & Company, the manufacturer of certain blood collection tubes used alongside these tests‍​.‍U.S. FDA-Report issued at conclusion of inspection of BD’s Franklin Lakes, New Jersey facility includes observations that may be violations of federal law​.u.s. fda - at this time, not determined that Becton Dickinson tubes,any other brand of tube linked to cause of the inaccurate lead test results‍​.U.S. FDA-Reviewing evidence collected from inspection of BD’s facility to decide if there were violations of federal law & if further action is warranted.FDA-Conducted inspection of becton dickinson‍​ facility to understand what caused inaccurate results associated with magellan diagnostics’ leadcare tests.  Full Article

C.R. Bard shareholders approve proposed merger with Becton Dickinson
Tuesday, 8 Aug 2017 04:54pm EDT 

Aug 8 (Reuters) - Becton Dickinson And Co :Bard shareholders approve proposed merger with becton, dickinson.Becton dickinson and co - ‍proposed transaction is presently expected to close in fourth calendar quarter of 2017​.  Full Article

Becton Dickinson and Co reports Q3 loss per share $0.75
Thursday, 3 Aug 2017 06:00am EDT 

Aug 3 (Reuters) - Becton Dickinson And Co :BD announces results for 2017 third fiscal quarter.Q3 loss per share $0.75.Q3 revenue $3.035 billion versus I/B/E/s view $3.06 billion.Q3 earnings per share view $2.44 -- Thomson Reuters I/B/E/S.Raises FY 2017 earnings per share view to $5.10 to $5.15.Q3 adjusted earnings per share $2.46.Sees FY 2017 revenue down 3 to 3.5 percent.Raises FY 2017 adjusted earnings per share view to $9.42 to $9.47.FY2017 earnings per share view $9.45, revenue view $12.06 billion -- Thomson Reuters I/B/E/S.Becton Dickinson and Co-sees FY 2017 revenue up 4.5-5.0 percent on comparable,currency-neutral basis that excludes respiratory solutions,other divestitures​.Becton Dickinson and Co - ‍ Q3 loss per share primarily due to a non-cash charge from modification to dispensing lease contracts with customers.Becton Dickinson and Co - ‍on currency-neutral basis, co continues to expect full fiscal 2017 adjusted diluted EPS to be between $9.70 and $9.80​.  Full Article

Becton Dickinson extends exchange for C. R. Bard, Inc. notes
Tuesday, 1 Aug 2017 06:55am EDT 

Aug 1 (Reuters) - Becton Dickinson And Co ::BD announces extension of exchange offers and consent solicitations for C. R. Bard, Inc. Notes.Becton dickinson - amended exchange offers, consent solicitations to extend expiration date of exchange offers and consent solicitations to August 29.  Full Article

BD reports extension of exchange offers and consent solicitations for C. R. Bard notes
Monday, 3 Jul 2017 06:00am EDT 

July 3 (Reuters) - Becton Dickinson and Co ::BD announces extension of exchange offers and consent solicitations for C. R. Bard Inc notes.Becton Dickinson And Co - amended exchange offers and consent solicitations to extend expiration date to 12:01 a.m., New York City time, on Aug 1​.  Full Article

FlowJo says established a strategic relationship with Becton Dickinson to catalyze coordination of resources for research market
Tuesday, 13 Jun 2017 06:59am EDT 

June 13 (Reuters) - Becton Dickinson And Co :Flowjo- Co, Becton Dickinson have established a strategic relationship to catalyze coordination of resources, people and data for research market.Flowjo says under agreement, companies are collaborating to offer cloud-based platform, flowjo envoy, with bd facsymphony.  Full Article